文献速递临床试验与 GCP基础与转化研究

HA380血液灌流用于急性A型主动脉夹层主动脉弓手术患者(HPAO):随机对照双盲临床试验

Hemoperfusion with HA380 in acute type A aortic dissection patients undergoing aortic arch operation (HPAO): a randomized, controlled, double-blind clinical trial.
PubMed 文献 · Trials · 2020-11-23

本研究为单中心随机对照双盲试验,计划纳入88例接受体外循环(CPB)和深低温停循环(DHCA)修复主动脉弓的急性A型主动脉夹层(ATAAD)患者,等比例随机分为对照组(仅CPB/DHCA)和干预组(CPB/DHCA+HA380血液灌流),每组44例。主要结局是围术期主要并发症复合终点,次要结局包括炎症标志物、凝血参数、围术期全因死亡率、ICU停留时间和总住院费用。试验旨在验证HA380降低围术期促炎细胞因子水平的安全性和有效性,并评估其是否改善患者结局。

要点

  • HA380血液灌流可能降低ATAAD患者CPB/DHCA期间的炎症细胞因子水平。
  • 主要结局为围术期主要并发症复合终点,每组44例。
  • 次要结局包括炎症标志物、凝血参数、死亡、ICU停留和住院费用。

核心结论

  • 试验旨在验证HA380血液灌流在ATAAD患者CPB/DHCA期间降低促炎细胞因子水平的安全性和有效性,并评估其是否改善患者结局。

研究设计与样本

  • 单中心、随机、对照、双盲临床试验,计划招募88例ATAAD伴主动脉弓受累接受CPB和DHCA修复的患者,等比例随机分为对照组和干预组各44例。

主要发现

  • 原文未报告试验结果。

关键数值与推荐

  • 主要结局为围术期主要并发症复合终点。
  • 次要结局包括相关炎症标志物、凝血参数和围术期次要并发症。
  • 还将评估围术期全因死亡率、ICU停留时间和总住院费用的差异。

临床怎么用

  • 若试验证实有效,HA380血液灌流可能作为ATAAD患者CPB/DHCA期间减轻炎症反应的辅助措施。

局限性

  • 单中心设计可能影响结果外推。
  • 试验注册为回顾性注册(2019年7月1日)。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Cardiopulmonary bypass (CPB) is an important cause of significant systemic inflammatory response syndrome (SIRS) in the surgical treatment of acute type A aortic dissection (ATAAD). In patients with arch vessel involvement, extensive surgical repairs often necessitate prolonged use of CPB and results in extensive inflammatory responses. Cytokines and chemokines released during CPB contribute to the progression of SIRS, increase perioperative complications, and negatively impact surgical outcomes. A cytokine adsorber (HA380) is expected to reduce the level of cytokines during CPB, which may decrease both intraoperative and postoperative inflammation. The purpose of this study is to investigate if HA380 is able to reduce the levels of inflammatory cytokines and decrease perioperative complications in ATAAD patients undergoing CPB and deep hypothermic circulatory arrest (DHCA). METHODS: This study is a single-center, randomized, controlled, double-blind clinical trial. The study aims to recruit 88 patients with ATAAD and aortic arch involvement who will undergo CPB and DHCA to repair the dissected aorta. Patients will be randomized equally into the CPB/DHCA only group (control group) and the CPB/DHCA + HA380 hemoperfusion group (intervention group), with 44 patients each. Patients in the control group will undergo CPB and DHCA only, while patients in the intervention group will undergo continuous hemoperfusion with HA380, in addition to CPB and DHCA. The primary outcome is a composite of major perioperative complications. The secondary outcomes include related inflammatory markers, coagulation parameters, and minor perioperative complications. To comprehensively evaluate the effect of hemoperfusion on the perioperative outcomes, we will also determine if there are differences in perioperative all-cause mortality, length of ICU stay, and total hospitalization costs. DISCUSSION: In the current trial, hemoperfusion will be applied in patients undergoing CPB and DHCA for repair of the aorta involving the aortic arch. This trial aims to test the safety and efficacy of our hemoperfusion device (HA380) in such settings. Upon completion of the trial, we will determine if HA380 is effective in reducing perioperative proinflammatory cytokine levels. Further, we will also verify if reduction in the proinflammatory cytokine levels, if present, translates to improvement in patient outcomes. TRIAL REGISTRATION: ClinicalTrials.gov NCT04007484 . Registered on 1 July 2019 (retrospectively registered).

来源:Trials,查看原文。版权归原作者所有。

引用

  1. Yang J, Ji D, Zhu YQ, et al. Hemoperfusion with HA380 in acute type A aortic dissection patients undergoing aortic arch operation (HPAO): a randomized, controlled, double-blind clinical trial. Trials. 2020. PMID: 33228727. doi:10.1186/s13063-020-04858-2

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。